英伯克斯生物科技
INBX
89.83
-0.67
-0.74%
英伯克斯生物科技
US · INBX
#3022 按市值排名
上市于 2024
89.83
-0.67
-0.74%
实时 - 追踪5344个代码 - 心跳于81秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量增加了1家。
- 机构持股总比例下降了9.0个百分点。
机构持股
- 机构持股比例
- 99.53% -9.00pp
- 机构数量
- 198 +1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund32.71%
Hedge Fund25.65%
Public Company25.61%
Individual/Insider15.56%
VC/PE Fund10.88%
Government Pension Fund2.98%
Private Company0.91%
Sovereign Wealth Fund0.62%
Family Office/Trust0.18%
主要股东 截至 2026-06-30
Viking Global Investors LP
9.40% · 1.38M 股
Morgan Stanley
8.87% · 1.31M 股
Perceptive Advisors LLC
8.82% · 1.30M 股
Sanofi
7.87% · 1.16M 股
John Kayyem
7.30% · 1.07M 股
Mark Lappe
6.53% · 960.41K 股
HighTower Advisors, LLC
5.92% · 870.55K 股
Bank of America Corporation
5.72% · 841.14K 股
BlackRock
5.61% · 825.97K 股
Schonfeld Strategic Advisors LLC
4.74% · 697.59K 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪27份申报 · 0次买入 · 27次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| John Kayyem | Independent Director | 7.30% |
| Mark Lappe | Chairperson & CEO | 6.53% |
| Douglas Forsyth | Independent Director | 1.54% |
| Kristiina Vuori | Independent Director | 0.14% |
| Kimberly Manhard | Independent Director | 0.05% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2024-05-29 | Douglas Forsyth | Independent Director | Sale to Issuer | -598,257 | $30.00 |
| 2024-05-29 | Douglas Forsyth | Independent Director | Derivative Sale to Issuer | -62,259 | -- |
| 2024-05-29 | Kimberly Manhard | Independent Director | Derivative Sale to Issuer | -65,759 | -- |
| 2024-05-29 | John Kayyem | Independent Director | Sale to Issuer | -3,274,301 | $30.00 |
| 2024-05-29 | John Kayyem | Independent Director | Derivative Sale to Issuer | -62,259 | -- |
| 2024-05-29 | Mark Lappe | Chairperson & CEO | Sale to Issuer | -3,045,654 | $30.00 |
| 2024-05-29 | Mark Lappe | Chairperson & CEO | Derivative Sale to Issuer | -245,000 | -- |
| 2024-05-29 | Kristiina Vuori | Independent Director | Derivative Sale to Issuer | -60,000 | -- |
| 2024-05-29 | Brendan Eckelman | Founder & Chief Scientific Officer | Sale to Issuer | -2,055,553 | $30.00 |
| 2024-05-29 | Brendan Eckelman | Founder & Chief Scientific Officer | Derivative Sale to Issuer | -33,334 | -- |
| 2024-05-29 | Kelly Deck | Chief Financial Officer | Derivative Sale to Issuer | -45,000 | -- |
| 2024-05-27 | Brendan Eckelman | Founder & Chief Scientific Officer | Open Market Disposition | -300,000 | $34.30 |
| 2024-05-21 | Brendan Eckelman | Founder & Chief Scientific Officer | Other Derivative Disposition | -5,010 | $23.30–33.63 |
| 2024-05-05 | Kelly Deck | Chief Financial Officer | Intent to Sell (Form 144) | -19,711 | $34.24 |
| 2024-03-25 | Kelly Deck | Chief Financial Officer | Other Derivative Disposition | -2,896 | $10.52–34.16 |
| 2024-03-21 | Kelly Deck | Chief Financial Officer | Intent to Sell (Form 144) | -110 | $35.00 |
| 2024-03-20 | Kelly Deck | Chief Financial Officer | Intent to Sell (Form 144) | -3,113 | $35.09 |
| 2024-03-19 | Kelly Deck | Chief Financial Officer | Intent to Sell (Form 144) | -16,777 | $35.02 |
| 2024-03-12 | Brendan Eckelman | Founder & Chief Scientific Officer | Other Derivative Disposition | -1,898 | $33.63 |
| 2024-03-12 | Kelly Deck | Chief Financial Officer | Other Derivative Disposition | -32,431 | $11.25 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
英伯克斯生物科技 讨论区 0 条评论